Cobimetinib

Drug Profile

Cobimetinib

Alternative Names: Cobimetinib fumarate; Cotellic; GDC-0973; RG-7421; RO 5514041; XL-518

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Exelixis
  • Developer Exelixis; Genentech; Memorial Sloan-Kettering Cancer Center; Roche; University Hospital Tubingen
  • Class Antineoplastics; Azetidines; Fluorobenzenes; Iodobenzenes; Small molecules
  • Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma
  • Phase III Colorectal cancer
  • Phase II Breast cancer; Histiocytosis
  • Phase I/II Solid tumours

Most Recent Events

  • 11 Jan 2017 Genentech collaborates with NCI Formulary to co-develop cobimetinib in Cancer
  • 09 Jan 2017 Genentech has withdrawn the counter-claims against Exelixis
  • 01 Jan 2017 Roche initiates enrolment in the phase III IMspire150 TRILOGY trial in Malignant melanoma (Combination therapy, Metastatic disease, First-line therapy, late-stage disease) in USA, Germany, New Zealand, Spain (NCT02908672)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top